Alnylam Pharmaceuticals, Inc. vs Vertex Pharmaceuticals Incorpor
A head-to-head of Alnylam Pharmaceuticals, Inc. (ALNY) and Vertex Pharmaceuticals Incorpor (VRTX) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | ALNY | VRTX |
|---|---|---|
| Market Cap | $35.71B | $123.26B |
| P/E (TTM) | 73.08 | 28.80 |
| Forward P/E | 21.24 | 20.21 |
| P/S | 9.77 | 9.03 |
| P/B | 33.19 | 6.38 |
| EV/EBITDA | 44.53 | 21.08 |
| Dividend Yield | — | — |
| Profit Margin | 13.46% | 35.51% |
| Gross Margin | 81.64% | 86.24% |
| Operating Margin | 13.51% | 37.95% |
| Revenue Growth (YoY) | +96.43% | +7.82% |
| FCF Yield | 1.54% | 3.36% |
| Debt / Equity | 93.86 | 10.26 |
| Current Ratio | 3.13 | 3.02 |
Which is better: Alnylam Pharmaceuticals, Inc. or Vertex Pharmaceuticals Incorpor?
- ✓Larger by market cap: Vertex Pharmaceuticals Incorpor
- ✓Cheaper valuation (lower P/E): Vertex Pharmaceuticals Incorpor
- ✓More profitable (net margin): Vertex Pharmaceuticals Incorpor
- ✓Faster revenue growth: Alnylam Pharmaceuticals, Inc.
- ✓Higher free-cash-flow yield: Vertex Pharmaceuticals Incorpor
Across 12 available metrics, Vertex Pharmaceuticals Incorpor leads 10–2.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
Compare Alnylam Pharmaceuticals, Inc. with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.